At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
everolimus +1 moredrug
Likely dose
everolimus 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors
Sarcoma Alliance for Research through Collaboration·interventional·Posted Aug 9, 2012·Updated Mar 6, 2019
In Brief
A Phase 2 clinical trial evaluating everolimus and bevacizumab for Malignant Peripheral Nerve Sheath Tumors and 2 related conditions. Completed, enrolled 25 participants across 12 sites.
Detailed Summary
To determine the clinical response rate of everolimus in combination with bevacizumab for patients with chemotherapy refractory sporadic or neurofibromatosis type 1 (NF1) associated malignant peripheral nerve sheath tumor (MPNST). To evaluate the toxicity and safety of everolimus in combination with bevacizumab in individuals with MPNST
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Peripheral Nerve Sheath Tumors, MPNST, Sarcoma
CountriesUnited States
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 2012
Enrollment StartSep 2012
Primary CompletionJun 2017
Study CompletionDec 2017
TodayJul 2026
First PostedAug 9, 2012
Enrollment StartSep 1, 2012
Primary CompletionJun 1, 2017
Study CompletionDec 1, 2017
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 13.9 years ago
Interventions
everolimusdrug
10 mg tablet once daily
bevacizumabdrug
10 mg/kg dose every 14 days